Additionally, studies in B-cell lymphoma and non-small cell lung cancer (NSCLC) indicated that XPO1 mutations may result in resistance to conventional chemotherapy; however, cells with mutated XPO1 demonstrated increased sensitivity to XPO1 inhibitors so that the therapeutic remained effective [28,29]. The gene discussed is XPO1; the disease is B-cell non-Hodgkin lymphoma.